Sanofi Says Tolebrutinib Demonstrated 31% Delay In Time To Onset Of Confirmed Disability Progression In Non-relapsing Secondary Progressive Multiple Sclerosis Phase 3 Study; Global Regulatory Submissions Will Begin In H2 2024
Portfolio Pulse from Nabaparna Bhattacharya
Sanofi's phase 3 study of tolebrutinib shows a 31% delay in disability progression for non-relapsing secondary progressive multiple sclerosis patients. Global regulatory submissions are planned for H2 2024.
September 20, 2024 | 9:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sanofi's tolebrutinib demonstrated a 31% delay in disability progression in a phase 3 study for nrSPMS, with regulatory submissions planned for H2 2024.
The positive phase 3 results for tolebrutinib in delaying disability progression in nrSPMS patients are significant for Sanofi, indicating potential future revenue from this treatment. The planned regulatory submissions in H2 2024 suggest a clear path towards market approval, which could positively impact Sanofi's stock price in the short term as investors anticipate future earnings.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100